30mg Cytopoint is indicated for the treatment of clinical manifestations of atopic dermatitis in dogs. Pack of 2 Vials. VETERINARY PRESCRIPTION REQUIRED
Warning: Last items in stock!
|Target Animal:||Dog (Canine)|
|Related Condition:||Atopic Dermatitis in Dogs|
|Pet Prescription Required?:||Yes|
|Active Ingredient:||Monoclonal antibody|
|Product Name:||30mg Cytopoint for Dogs|
|Pack Size:||Pack of 2 Vials|
Cytopoint may only be supplied with a valid veterinary prescription, issued by your vet. You should only purchase Cytopoint if you have or are in the process of arranging such a prescription. See information bar for further details.
Therapeutic indication: Immunological veterinary medical product (non vaccine): For dogs
Active ingredient: Monoclonal antibody
Presentation Each Cytopoint vial of 1 ml contains 10, 20, 30 or 40 mg Lokivetmab.
Lokivetmab is a caninised monoclonal antibody expressed through recombinant techniques in Chinese hamster ovary (CHO) cells.
Uses: Cytopoint is indicated for the treatment of clinical manifestations of atopic dermatitis in dogs.
Dosage and administration
For subcutaneous use. Avoid excessive shaking or foaming of the solution. Administer the entire contents (1 ml) of the Cytopoint vial. For dogs above 40 kg, the contents of more than one vial of Cytopoint are required to administer in a single dose. In those cases, withdraw the appropriate content from each required vial into the same syringe. To allow for mixing of the solution, gently invert the syringe three or four times before administering. Dosage and treatment schedule The recommended minimum dose is 1 mg/kg bodyweight, once a month.
Contra-indications, warnings, etc
Do not use Cytopoint in cases of hypersensitivity to the active substance or to any of the excipients. Do not use in dogs less than 3kg bodyweight. Lokivetmab may induce transient or persistent anti-drug antibodies. The induction of such antibodies is uncommon and may have no effect (transient anti-drug antibodies) or may result in a noticeable decrease in efficacy (persistent anti-drug antibodies) in animals that responded to treatment previously. In cases of atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange). It is recommended to monitor dogs for bacterial infections associated with atopic dermatitis, especially during the first weeks of treatment. If no or limited response is observed within one month after initial dosing, an improvement in response may be observed after administration of a second dose one month later. However, if the animal does not show a better response after the second dose, the veterinary surgeon should consider alternative treatments. The safety of the veterinary medicinal product has not been established during pregnancy and lactation; therefore its use is not recommended during pregnancy, lactation or in breeding animals. No drug interactions were observed in field studies where lokivetmab was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials, anti-inflammatories and vaccines. If a vaccine(s) is to be administered at the same time as treatment with lokivetmab, the vaccine(s) should be administered at a different site to that of lokivetmab administration.
Do not mix Cytopoint with any other veterinary medicinal product. Hypersensitivity reactions (anaphylaxis, facial oedema, urticaria) may occur in rare cases. In such cases appropriate treatment should be administered immediately. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). No adverse reactions other than those mentioned above were observed in laboratory overdose studies. In case of adverse clinical signs after an overdose the dog should be treated symptomatically. User warnings Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case of accidental self-injection. Accidental self-injection may result in an immune response to lokivetmab. It is not expected for this to cause any adverse effects, however, repeated self-administration may increase the risk of hypersensitivity reactions. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Store in a refrigerator (2°C - 8°C). Do not freeze. Store in the original package. Protect from light. Shelf life after first opening the immediate packaging: use immediately Keep out of the sight and reach of children. For animal treatment only.
Cytopoint is a POM-V (Pet Prescription Required)
Supplied in boxes of 2 vials